LOCATION: Oklahoma City
OCAST PROGRAM: OSCR
FUNDING: $220,099 grant from the National Institutes of Health
The American Cancer Society estimated that in 2013 alone, 45,220 people in the United States would be diagnosed with pancreatic cancer. Of those, 38,460 are estimated to die from the disease. Pancreatic cancer is the fourth leading cause of cancer deaths with a median survival range of only six months after diagnosis.
The researchers at COARE Biotechnology are challenging these disheartening statistics with what they hope will eventually be a treatment, even a cure, for pancreatic cancer. The team at COARE has identified a protein they believe to be very influential in the growth and movement of cancer stem cells. They believe that blocking this protein will either prevent the tumor from forming or keep it from growing.
With help from OCAST’s and i2E’s Oklahoma SBIR Collaborative Resources (OSCR) program, the team at COARE was recently awarded a Phase I Small Business Innovation Research grant. Funding will enable researchers to test various treatments to target the protein, continue their research and move closer to bringing a treatment to market.
COARE is working on a treatment, or even a cure, for pancreatic cancer.
Last Modified on 01/09/2014